|Traded as||NYSE: GKOS|
|Headquarters||San Clemente, California, United States|
|Thomas Burns (President and CEO)|
|US$14,100,000 (loss) (2014)|
|Footnotes / references
Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure. As of 2015[update], the iStent was the smallest device ever approved by the United States Food and Drug Administration. The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T.
In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock. The proposed stock symbol for the company was "GKOS".
Glaukos' president and chief executive officer (CEO) Thomas Burns says Glaukos was the first to develop micro-stents for the treatment of glaucoma and is well ahead of its competitors. The CEO of MicroOptx, Chris Pulling, has stated that Glaukos is his "most direct" competitor.
Founded in 2001 by Olav Bergheim, Richard Hill and Mory Gharib, the company has raised $156 million in venture funding from Versant Ventures, OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Meritech Capital Partners, Domain Associates, Fjord Capital Management and Montreux Equity Partners.
- House, Douglas W. (19 June 2015). "Glaukos on deck for IPO". Seeking Alpha.
- Norman, Jan (27 September 2012). "O.C. glaucoma treatment firm Glaukos makes 'Next Big Thing' list". The Orange County Register. Retrieved 1 October 2012.
- Grayson, Katharine (18 June 2015). "Startup with tiny glaucoma implant snags $2.4M". Minneapolis/St. Paul Business Journal.
- Freeman, L. Neal (15 June 2015). "CPT coding for glaucoma surgery reporting undergoes changes". Ophthalmology Times. North Olmsted, Ohio: Medical Communications Group.
|This corporation or company article is a stub. You can help Wikipedia by expanding it.|